Relationship between ATAD3A expression level in gastric cancer tissue and chemotherapy sensitivity and prognosis
10.3760/cma.j.cn341190-20230218-00114
- VernacularTitle:胃癌组织中ATAD3A表达水平与化疗敏感性及预后的关系
- Author:
Rui SHI
1
;
Qingshan LIU
;
Yan WU
Author Information
1. 山东省第二康复医院消化科，泰安 271000
- Keywords:
Stomach neoplasms;
Adenosine triphosphatases;
Drug therapy,combination;
Antineoplastic combined chemotherapy protocols;
Susceptibility;
Disease-free surviv
- From:
Chinese Journal of Primary Medicine and Pharmacy
2023;30(9):1285-1290
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the relationship between ATPase Family AAA Domain Containing 3A (ATAD3A) expression level in gastric cancer tissue and chemotherapy sensitivity and prognosis.Methods:Eighty-six patients with advanced gastric cancer admitted to Shandong Second Rehabilitation Hospital from June 2020 to July 2021 were included in this study. Gastric cancer tissue and paracancer tissue samples were collected. ATAD3A expression level in gastric cancer tissue was detected using immunohistochemical staining with the SP method. ATAD3A expression was compared between gastric cancer tissue and paracancer tissue. The relationship between ATAD3A expression and clinical pathological parameters was analyzed. The relationship between ATAD3A expression level in gastric cancer tissue and chemotherapy sensitivity and prognosis was analyzed.Results:The ATAD3A-positive expression rate in the gastric cancer tissue was 75.58% (65/86), which was significantly higher than 43.02% (37/86) in the paracancer tissue ( χ2 = 18.89, P < 0.001). The expression level of ATAD3A in gastric cancer tissues was not correlated with gender, age, tumor diameter, clinical stage or lymph node metastasis (all P > 0.05). The proportion of low differentiation and distant metastasis in patients with ATAD3A-positive expression was significantly higher than that in patients with ATAD3A-negative expression ( χ2 = 5.71, 6.17, both P < 0.05). The total response rate of chemotherapy in patients with ATAD3A-positive expression was 60.00% (39/65), which was significantly lower than 85.71% (18/21) in patients with ATAD3A-negative expression ( χ2 = 4.55, P = 0.033). Of 86 patients, 59 were sensitive to paclitaxel and 56 to capecitabine. The sensitivity of paclitaxel and capecitabine in the ATAD3A-positive group was lower than that in the blank control group ( χ2 = 6.17, 5.19, both P < 0.05). After 1 year of follow-up, the cumulative survival rate in patients with ATAD3A-positive expression was 43.08% (28/65), which was significantly lower than 71.43% (15/21) in patients with ATAD3A-negative expression ( χ2 = 5.24, P < 0.05). The survival time of patients with ATAD3A-positive expression was (8.47 ± 2.13) months, which was significantly shorter than (13.62 ± 1.49) months for patients with ATAD3A-negative expression ( t = 6.29, P < 0.05). Cox multivariate regression analysis showed low differentiation ( HR = 6.22, 95% CI: 1.537-25.240), distant metastasis ( HR = 2.57, 95% CI: 1.396-4.742), and positive expression of ATAD3A ( HR = 10.60, 95% CI: 2.631-42.715) were independent factors that affect the survival time of patients with gastric cancer after chemotherapy ( P < 0.05). Conclusion:ATAD3A is expressed in gastric cancer tissue. Its expression level is closely related to chemotherapy sensitivity and prognosis. It provides an important reference value for the evaluation of chemotherapy efficacy and prognosis.
